Recent Advances in Systemic Therapy for Hepatocellular Carcinoma

Area of Science:

• Hepatobiliary Cancers
• Medical Oncology
• Translational Research

Background:

• Hepatocellular carcinoma (HCC) is frequently diagnosed at late stages, leading to poor median survival.
• Surgical resection, the primary treatment for localized HCC, is often not feasible due to tumor burden or liver dysfunction.
• Limited effective systemic therapies were available for advanced HCC until recent advancements.

Purpose of the Study:

• To review the evolving landscape of systemic treatments for advanced hepatocellular carcinoma.
• To highlight the impact of novel therapeutic agents on patient survival and treatment options.

Main Methods:

• Review of clinical trial data and published literature on systemic therapies for advanced HCC.
• Analysis of survival outcomes for targeted agents, immune checkpoint inhibitors, and combination therapies.
• Comparison of efficacy between different systemic treatment modalities and best supportive care.

Main Results:

• Molecularly targeted agents (sorafenib, regorafenib, lenvatinib) have demonstrated survival benefits over best supportive care.
• Second-line treatments including ramucirumab and immune checkpoint inhibitors show efficacy in progression or non-response.
• The combination of atezolizumab plus bevacizumab demonstrated superiority over first-line sorafenib.

Conclusions:

• Recent advancements in systemic therapy have dramatically altered the treatment paradigm for advanced HCC.
• Targeted therapies and immunotherapies offer viable and improved survival options for patients with advanced disease.
• The combination of immunotherapy and anti-angiogenic therapy represents a significant breakthrough in first-line treatment.